Immunovant, Inc. (IMVT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$29.90+2.96%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · IMVT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
IMVT — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Immunovant, Inc. (“the Company”) issued a press release announcing its financial results for its fiscal first quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…
Why it matters: The CLE trial is fully enrolled. Its first data will test whether IMVT-1402 can help in another disease.
Watch forThe company reports topline CLE data in 2026 and shows a clear benefit on the trial's main measure.
Also watch forThe main measure is missed, or topline data slip past 2026.
Why it matters: The early Week 16 results came from an open-label period. The later blinded results can test whether the response holds.
Watch forThe company reports Week 28 ACR20 results, and more patients on IMVT-1402 keep their response than on placebo.
Also watch forThe Week 28 results show no clear gap in maintained ACR20 response between IMVT-1402 and placebo.
Why it matters: R&D costs rose as IMVT-1402 trials advanced. Further increases could use cash faster than the stated launch runway allows.
Worry ifQuarterly R&D expense tops $142.6 million, the June 2026 quarter level, while cash falls below $797.8 million.
Less concerning ifQuarterly R&D expense stays at or below $142.6 million, or cash rises above $797.8 million.
Why it matters: The company has six active disease programs and rising trial costs. Delays or faster cash use could weaken its path to a Graves' disease launch.
Watch forOn Nov. 9, the company keeps its planned trial dates and reports cash runway still reaching a possible Graves' disease launch.
Also watch forOn Nov. 9, the company delays a key trial date or says cash no longer reaches a possible Graves' disease launch.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$158 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $451 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,055 loss on $10,000 · 40.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: These are planned results from trials that could support registration. A delay or weak result would challenge the lead program.
Watch forThe company reports top-line data from both planned trials in 2027. The results may support further development.
Also watch forEither result misses its main trial goal, or data from either trial move past 2027.